Evidence map›Paper›PMID 40295207›Full record

ArticleJournal of the Pediatric Infectious Diseases Society2025

Readmission Following Respiratory Syncytial Virus Hospitalization among Children <5 Years of Age.

Yoonyoung Choi, Evan Heller, Linda Amoafo, Yue Zhang, Kaleb Miller, Abbey Loveridge, Madelyn Ruggieri, Per Gesteland, Krow Ampofo

Abstract read
In one paragraph

Article in Journal of the Pediatric Infectious Diseases Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yoonyoung ChoiValue & Implementation, Merck & Co., Inc., Rahway, NJ, United States.
Evan HellerDepartment of Pediatrics, University of Utah, Salt Lake City, UT, United States.
Linda AmoafoDepartment of Population Health Sciences, University of Utah, Salt Lake City, UT, United States.
Yue ZhangDepartment of Population Health Sciences, University of Utah, Salt Lake City, UT, United States.
Kaleb MillerDepartment of Pediatrics, University of Utah, Salt Lake City, UT, United States.
Abbey LoveridgeDepartment of Pediatrics, University of Utah, Salt Lake City, UT, United States.
Madelyn RuggieriValue & Implementation, Merck & Co., Inc., Rahway, NJ, United States.
Per GestelandDepartment of Pediatrics, University of Utah, Salt Lake City, UT, United States.
Krow AmpofoDepartment of Pediatrics, University of Utah, Salt Lake City, UT, United States.

Funding

Merck Sharp & Dohme LLCMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA
6 · The paper itself

Abstract

backgroundHospitalization with lower respiratory infection (LRI) by Respiratory Syncytial Virus (RSV) and other respiratory viruses is common in young children. However, the likelihood of readmission following RSV LRI compared to other common respiratory viral infections is unknown.

methodsThis prospective study included children <5 years and hospitalized with laboratory-confirmed RSV LRI at two hospitals in Salt Lake City, Utah, from October 31, 2019 to April 30, 2022. For comparison, we retrospectively identified children <5 years, hospitalized during the same period with Influenza virus (IV) or human metapneumovirus (hMPV) LRI. Readmissions were tracked for 1.5 years post-discharge. We calculated the incidence proportion of readmissions and estimated hazard ratios using Cox proportional hazards model with Covariate Balancing Propensity Score.

resultsAmong children hospitalized with RSV, IV, and hMPV LRI, all-cause hospital readmission was common, with 30-day readmission proportions ranging between 5% and 9% and increasing to between 19% and 30%, 1.5 years post-discharge. Respiratory-related readmission varied by virus, with RSV having higher proportions, increasing to 16.8% 1.5 years post-discharge, compared to 6%-7% with IV and hMPV. After adjusting for confounders, RSV hospitalization was associated with an increased hazard of respiratory-related readmission within 1.5 years after hospitalization compared to IV (HR 3.62, 95% CI, 1.13-11.64) or hMPV (HR 3.56, 95% CI, 1.14-11.06).

conclusionRespiratory-related readmission proportion was higher and progressive over time among children <5 years with an index RSV admission compared to IV and hMPV. This underscores the critical need for prevention of RSV infection in infants and young children through RSV immunization strategies.

Indexed as

HospitalizationPatient ReadmissionRespiratory Syncytial Virus InfectionsRespiratory Tract InfectionsChild, PreschoolFemaleHumansIncidenceInfantInfluenza, HumanMaleMetapneumovirusParamyxoviridae InfectionsProportional Hazards ModelsProspective StudiesRespiratory Syncytial Virus, Humanhuman metapneumovirusinfluenza viruslower respiratory infection hospitalizationreadmissionRespiratory Syncytial Virus

Identifiers

PMID40295207
PMCPMC12123188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.